In a nutshell This study evaluated nivolumab (Opdivo) plus brentuximab vedotin (Adcetris) in patients with relapsed or unresponsive primary mediastinal B-cell lymphoma (PMBCL). This study concluded that this combination is promising and was well-tolerated. Some background PMBCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL)....
Read MoreCurrent treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor
Searching for participants with high risk relapsed or unresponsive Hodgkin lymphoma to try a treatment combination.
In a nutshell This study will investigate the effects of nivolumab (Opdivo) and brentuximab vedotin (Adcetris) after stem cell transplant in patients with high risk relapsed or refractory Hodgkin lymphoma (RRHL). The main outcome that will be measured is progression-free survival. This trial is recruiting in multiple locations in the United States. The...
Read MoreSalvage treatment for patients with relapsed/unresponsive acute myeloid leukemia
In a nutshell This study aimed to investigate if the combination of cladribine, cytarabine, and granulocyte colony-stimulating factor (G-CSF) could act as salvage treatment for patients with relapsed or unresponsive acute myeloid leukemia. This study concluded that this treatment was safe and effective in...
Read MoreLooking for participants with advanced colorectal cancer to test a new combined treatment
In a nutshell This phase 1/2 trial is examining the effectiveness of liposomal irinotecan (LI; Onivyde) and rucaparib (Rubraca) in treating patients with advanced colorectal cancer. The main outcome to be measured will be the toxicity and tumor response to the treatment. This trial is being conducted in Arizona, Georgia, Minnesota, and Utah, US. The...
Read MoreT-cell therapy for relapsed/refractory multiple myeloma
In a nutshell This study aimed to investigate the safety of a T-cell therapy, bb2121, for patients with relapsed or unresponsive multiple myeloma. This study concluded that bb2121 shows antitumor activity in these patients. Some background Early studies indicate that bb2121 has potential to treat relapsed or unresponsive...
Read MoreSearching for patients with unresponsive cancer to test a new treatment
In a nutshell This phase 1/2 trial will investigate the safety of 9-ING-41, for treatment-resistant cancers. The main outcome will be the number of treatment-related adverse events (TRAEs). This trial is recruiting in the United States. The details Some cancers may not respond to conventional treatment. Treatment-resistant cancers are called...
Read MoreSearching for patients with recurrent or non-responsive lymphoma to try this new treatment option
In a nutshell This phase 1 study is evaluating the safety and effectiveness of a new T-cell therapy combined with nivolumab (Opdivo) for patients with lymphoma that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have side effects. This study is recruiting in Washington, D.C. and Salt...
Read MoreLooking for patients with advanced colorectal cancer to test a new drug
In a nutshell This phase 1 study will investigate the dose range and effectiveness of an experimental drug, XmAb23104, in the treatment of advanced colorectal cancer and other solid tumors. The main outcome will be the safety and tolerability of XmAb23104. This trial is recruiting in Georgia, Texas, and Virginia, the United States. The details...
Read MoreEvaluating high-dose etoposide before stem cell transplantation for patients with unresponsive diffuse large B cell lymphoma
In a nutshell This study evaluated the outcomes of patients with unresponsive diffuse B-cell lymphoma (DLBCL) after treatment with high-dose etoposide (Etopophos) and a stem cell transplant (SCT). This study concluded that this regimen was effective for some of these patients, namely those who responded to etoposide treatment. Some background DLBCL is...
Read MoreLooking for older patients with acute myeloid leukemia to test a new treatment combination
In a nutshell This study is evaluating how well CPI-613 plus chemotherapy works in older patients with acute myeloid leukemia (AML) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This trial is taking place across the United...
Read MoreLooking for young patients with non-Hodgkin’s lymphoma to test a treatment combination
In a nutshell This phase 3 trial is comparing the effectiveness of ibrutinib (Imbruvica) plus chemotherapy versus chemotherapy alone in children and young adults with B-cell non-Hodgkin’s lymphoma (NHL). The main outcome to be measured will be survival without cancer returning, growing or spreading. The details Ibrutinib is a targeted therapy...
Read MoreEvaluating quality of life after pembrolizumab treatment for classical Hodgkin lymphoma
In a nutshell This phase 2 study evaluated the impact of pembrolizumab (Keytruda) on the quality of life of patients with classical Hodgkin’s lymphoma (cHL) that has come back or stopped responding to treatment. This study concluded that the overall quality of life and health status was improved for these patients. Some background Most patients...
Read More
